250 related articles for article (PubMed ID: 27389085)
21. Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn's Disease.
Watanabe K; Matsumoto T; Hisamatsu T; Nakase H; Motoya S; Yoshimura N; Ishida T; Kato S; Nakagawa T; Esaki M; Nagahori M; Matsui T; Naito Y; Kanai T; Suzuki Y; Nojima M; Watanabe M; Hibi T;
Clin Gastroenterol Hepatol; 2018 Apr; 16(4):542-549.e1. PubMed ID: 29104132
[TBL] [Abstract][Full Text] [Related]
22. Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2).
Hisamatsu T; Kato S; Kunisaki R; Matsuura M; Nagahori M; Motoya S; Esaki M; Fukata N; Inoue S; Sugaya T; Sakuraba H; Hirai F; Watanabe K; Kanai T; Naganuma M; Nakase H; Suzuki Y; Watanabe M; Hibi T; Nojima M; Matsumoto T;
J Gastroenterol; 2019 Oct; 54(10):860-870. PubMed ID: 31041545
[TBL] [Abstract][Full Text] [Related]
23. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Nørgård BM
Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
[TBL] [Abstract][Full Text] [Related]
24. Pulmonary cryptococcosis in a patient with Crohn's disease treated with prednisone, azathioprine and adalimumab: exposure to chicken manure as a source of contamination.
Fraison JB; Guilpain P; Schiffmann A; Veyrac M; Le Moing V; Rispail P; Le Quellec A
J Crohns Colitis; 2013 Feb; 7(1):e11-4. PubMed ID: 22647638
[TBL] [Abstract][Full Text] [Related]
25. Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease.
Watanabe M; Hibi T; Mostafa NM; Chao J; Arora V; Camez A; Petersson J; Thakkar R
J Crohns Colitis; 2014 Nov; 8(11):1407-16. PubMed ID: 24874893
[TBL] [Abstract][Full Text] [Related]
26. Infliximab, azathioprine, or combination therapy for Crohn's disease.
Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens G; Diamond RH; Broussard DL; Tang KL; van der Woude CJ; Rutgeerts P;
N Engl J Med; 2010 Apr; 362(15):1383-95. PubMed ID: 20393175
[TBL] [Abstract][Full Text] [Related]
27. [Predictors of efficacy, mucosal healing and dose intensification during the first year of adalimumab therapy in patients with luminal and fistulizing Crohn's disease. National data from Hungary].
Kiss LS; Szamosi T; Molnár T; Miheller P; Lakatos L; Vincze A; Palatka K; Bartha Z; Gasztonyi B; Salamon A; Horváth G; Tóth GT; Farkas K; Banai J; Tulassay Z; Nagy F; Szenes M; Veres G; Lovász BD; Végh Z; Golovics PA; Szathmári M; Papp M; Lakatos PL
Orv Hetil; 2011 Sep; 152(36):1433-42. PubMed ID: 21865144
[TBL] [Abstract][Full Text] [Related]
28. Use of 6-mercapturine/azathioprine as the immunomodulator of choice for moderately active Crohn's disease: con.
Griffiths AM
Inflamm Bowel Dis; 2005 Feb; 11(2):200-2. PubMed ID: 15677915
[No Abstract] [Full Text] [Related]
29. [New therapeutic option for M. Crohn : SONIC study (study of biologic and immunomodulator naive patients in Crohn's disease)].
Fölsch UR; Nitschmann S
Internist (Berl); 2010 Sep; 51(9):1202-4. PubMed ID: 20658120
[No Abstract] [Full Text] [Related]
30. Early combined immunosuppression in Crohn's disease.
Badina L; Taddio A; Ventura A
Lancet; 2008 Jun; 371(9629):1995; author reply 1996-7. PubMed ID: 18555906
[No Abstract] [Full Text] [Related]
31. Use of 6-mercaptopurine/azathioprine as the immunomodulator of choice for moderately active Crohn's disease: pro.
Hyams JS
Inflamm Bowel Dis; 2005 Feb; 11(2):197-9. PubMed ID: 15677914
[No Abstract] [Full Text] [Related]
32. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients.
Baert F; Glorieus E; Reenaers C; D'Haens G; Peeters H; Franchimont D; Dewit O; Caenepeel P; Louis E; Van Assche G;
J Crohns Colitis; 2013 Mar; 7(2):154-60. PubMed ID: 22537637
[TBL] [Abstract][Full Text] [Related]
33. Use of 6-mercaptopurine/azathioprine as the immunomodulator of choice for moderately active Crohn's disease: balance.
Jacobstein DA; Baldassano RN
Inflamm Bowel Dis; 2005 Feb; 11(2):203-5. PubMed ID: 15677916
[No Abstract] [Full Text] [Related]
34. A case of molluscum contagiosum infection in a patient with Crohn's disease, receiving combination therapy with azathioprine and adalimumab.
Cintolo M; Guarneri C; Lentini M
J Crohns Colitis; 2015 Jul; 9(7):593-4. PubMed ID: 25908722
[No Abstract] [Full Text] [Related]
35. Treatment of Crohn's disease: the "long" of it.
Hanauer SB; Thisted RA
Gastroenterology; 2005 Jun; 128(7):2164-6. PubMed ID: 15940649
[No Abstract] [Full Text] [Related]
36. [Crohn's disease: no advantage by azathioprine and 6-mercaptopurine].
Schreiber S
Dtsch Med Wochenschr; 2013 Sep; 138(38):1877. PubMed ID: 24022448
[No Abstract] [Full Text] [Related]
37. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis.
Hazlewood GS; Rezaie A; Borman M; Panaccione R; Ghosh S; Seow CH; Kuenzig E; Tomlinson G; Siegel CA; Melmed GY; Kaplan GG
Gastroenterology; 2015 Feb; 148(2):344-54.e5; quiz e14-5. PubMed ID: 25448924
[TBL] [Abstract][Full Text] [Related]
38. Crohn's-like disease in a patient with common variable immunodeficiency treated with azathioprine and adalimumab.
Vázquez-Morón JM; Pallarés-Manrique H; Martín-Suárez IJ; Benítez-Rodríguez B; Ramos-Lora M
Rev Esp Enferm Dig; 2013; 105(5):299-302. PubMed ID: 23971663
[TBL] [Abstract][Full Text] [Related]
39. Clinical impact of immunomonitoring in the treatment of inflammatory bowel disease.
Tighe D; McNamara D
World J Gastroenterol; 2017 Jan; 23(3):414-425. PubMed ID: 28210077
[TBL] [Abstract][Full Text] [Related]
40. [New research results give hope. Causal therapy of Crohn disease in sight].
MMW Fortschr Med; 2004 Apr; 146(14):42-3. PubMed ID: 15344754
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
